Table 3.

Assessment of characteristic oxidative and inflammatory biomarkers and their statistical comparison to review the potential of amla preventive effects among healthy human subjects.

Parameters	Placebo intake (mean ± sem)				Amla intake (mean ± sem)				ANCOVA (Among Groups)
	Before (W1, W2) or (W10, W11)	2 Weeks (W3, W4) or (W12, W13)	4 Weeks (W5, W6) or (W14, W15)	Post (3 Weeks) (W7,W9,W9) or (W16,W17,W18)	Before (W1, W2) or (W10, W11)	2 Weeks (W3, W4) or (W12, W13)	4 Weeks (W5, W6) or (W14, W15)	Post (3 Weeks) (W7,W9,W9) or (W16,W17,W18)
TM (FU/mL)	1.98 ± 0.22	1.86 ± 0.21	2.10 ± 0.21	1.96 ± 0.26	2.05 ± 0.23	1.80 ± 0.27	1.64 ± 0.15	2.02 ± 0.27	2W: P = 0.67 4W: P = 0.16 Post: P = 0.86
		P = 0.68	P = 0.76	P = 1.0		P = 0.11	P = 0.12	P = 0.92
vWF (mU/mL)	9.05 ± 0.71	8.54 ± 0.51	8.73 ± 0.60	8.02 ± 0.56	10.2 ± 0.94	8.52 ± 082	8.22 ± 0.41	8.09 ± 0.48	2W: P = 0.27 4W: P = 0.58 Post: P = 0.18
		P = 0.56	P = 0.75	P = 0.28		P = 0.011*	P = 0.045*	P = 0.056*
TBARS (μM)	4.56 ± 1.11	4.96 ± 0.93	5.54 ± 0.73	4.55 ± 0.51	5.41 ± 1.33	3.18 ± 0.43	3.72 ± 0.67	4.99 ± 0.95	2W: P = 0.19 4W: P = 0.46 Post: P = 1.0
		P = 0.80	P = 0.54	P = 1.0		P = 0.14	P = 0.34	P = 0.80
8-OHdG (ng/mL)	0.25 ± 0.02	0.24 ± 0.03	0.24 ± 0.01	0.19 ± 0.02	0.27 ± 0.02	0.23 ± 0.03	0.21 ± 0.01	0.22 ± 0.02	2W: P = 0.22 4W: P = 0.002* Post: P = 0.003*
		P = 0.77	P = 0.60	P = 0.06		P = 0.033*	P = 0.036*	P = 0.031*
Adiponectin (ng/mL)	1.33 ± 0.19	1.47 ± 0.21	1.50 ± 0.21	1.51 ± 0.23	1.41 ± 0.23	1.32 ± 0.17	1.47 ± 0.19	1.40 ± 0.17	2W: P = 0.47 4W: P = 0.24 Post: P = 0.11
		P = 0.69	P = 0.63	P = 0.61		P = 0.86	P = 0.83	P = 1.0